SCHEMBL770807

SCHEMBL770807

O=C(CN1C(=O)c2ccc(F)cc2C1=O)N1CCCC2CCCC=C21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.37
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
TDP1 Q9NUW8 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
POLB P06746 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CACNA1G O43497 3/20 0.33
GAA P10253 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771033 0.90 ALDH1A1 (0.42) HSD17B10KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL786984 0.88 ALDH1A1 (0.44) HSD17B10MEN1KMT2ASMN1; SMN2POLB
SCHEMBL769977 0.87 ALDH1A1 (0.43) HSD17B10KMT2ASMN1; SMN2ALDH1A1HPGD
SCHEMBL770504 0.87 HSD17B10 (0.52) HSD17B10KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL770487 0.84 HSD17B10 (0.37) HSD17B10KDM4EMEN1KMT2ATDP1
SCHEMBL770404 0.81 HSD17B10 (0.40) HSD17B10KDM4EDDB1CRBNMEN1
SCHEMBL769981 0.79 HSD17B10 (0.40) HSD17B10KDM4EDDB1CRBNMEN1
SCHEMBL771129 0.77 KMT2A (0.41) HSD17B10KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL770734 0.76 ALDH1A1 (0.55) HSD17B10KDM4EKMT2ASMN1; SMN2POLB
SCHEMBL770859 0.74 ALDH1A1 (0.56) HSD17B10KMT2ASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HSD17B10 19/4885KDM4E 4127/4885DDB1 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.